Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Open accessThe DOI matches its Crossref record; 103 of the 107 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These agents not only improve glycemic control but also deliver robust cardiovascular and renal protection, with additional anti-inflammatory and antioxidative effects that modify the underlying pathophysiology of cardiometabolic disease [2,3].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373 · cited 1×
“ATP synthesis is crucial for the proper functioning of cardiomyocytes, and its production is impaired in failing hearts [64].”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 5×
“Subsequently, retatrutide entered a phase 2 clinical trial, aiming to develop it for the treatment of T2DM, obesity, and related comorbidities [101,103].”
InfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784 · cited 1×
“The increased utilization of FFA leads to an increment in lipolysis, promoting a reduction in inflammation mediated by adipose tissue, decreased oxidative stress and its damages, and reduced levels of circulating uric acid [57,58].”
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · cited 2×
“GIP receptor agonists belong to the same receptor family and Both compounds bind to their respective receptors on pancreatic β -cells, stimulating insulin secretion glucose-dependently [92,93].”
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
Diabetes and hypertension: the bad companions
Ferrannini, E., & Cushman, W. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60987-8 · Cited by 695 · cited 1×
“In addition, hyperinsulinemia causes vascular remodeling by promoting the proliferation of vascular smooth muscle and other cells, thereby reducing vascular stiffness [81].”
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“Instead, it has been demonstrated that GLP-1RA intake acts on weight loss through appetite suppression [86] and antiproliferative actions in vascular smooth muscle cells [87], which in turn could contribute to blood pressure reduction.”
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · cited 2×
“However, GLP1-RA increased the heart rate and the number of adverse cardiac events [50].”
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · cited 2×
“Studies have shown that these drugs offer cardioprotection in patients with established atherosclerotic cardiovascular disease, reduce the risk of admission to the hospital for heart failure, and lower cardiovascular and all-cause mortality [3].”
Role of insulin resistance in endothelial dysfunction
Muniyappa, R., & Sowers, J. R. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9229-1 · Cited by 539 · cited 1×
“Insulin resistance is considered one of the main causes of endothelial dysfunction, leading to reduced endothelium-dependent vasodilatory responses and, subsequently, hypertension [80].”
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15983-6 · Cited by 536 · cited 1×
“Specifically, they inhibit pro-inflammatory cytokines, such as IL-1 β , IL-6, and TNF-α , as well as attenuate NLRP3 inflammasome activation [70,71].”
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516 · cited 9×
“…several other mechanisms have been proposed, ranging from SGLT2i playing a role in sympathetic inhibition and autonomic cardiovascular regulation [1,42] to a hypothetical direct interaction of these compounds with atrial myocardium, which may ameliorate atrial electrical and structural…”
InfluentialXu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Hemodilution Is Common in Patients With Advanced Heart Failure
Androne, A.-S., Katz, S. D., Lund, L., LaManca, J., Hudaihed, A., Hryniewicz, K., & Mancini, D. M. (2003) · Circulation · doi:10.1161/01.cir.0000052623.16194.80 · Cited by 486 · cited 3×
“In the context of heart failure, low hematocrit is a common occurrence, which can arise from either haemodilution characterized by an increase in plasma volume or anemia that is marked by a decrease in red blood cell volume [51].”
InfluentialMarx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483 · cited 2×
“GLP1-RA exert a glucose-lowering effect, leading to a reduction in blood glucose and an improvement in postprandial glucose metabolism [67].”
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · cited 1×
“Furthermore, evidence has proven their neuroprotective role in reducing neuroinflamma-tion, protecting neurons against metabolic and oxidative insults, and promoting nerve growth [2].”
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 1×
“Subsequently, retatrutide entered a phase 2 clinical trial, aiming to develop it for the treatment of T2DM, obesity, and related comorbidities [101,103].”
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407 · cited 1×
“The weight loss achieved with tirzepatide in T2DM patients was accompanied by enhanced glycemic control, a healthier blood lipid profile, and reduced blood pressure [99].”
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Suthahar, N., Meijers, W. C., Silljé, H. H. W., & de Boer, R. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0343-y · Cited by 307 · cited 1×
“Cardiac inflammation and fibrosis are the primary pathological mechanisms operating in the failing heart, irrespective of the underlying etiology of heart failure [23].”
Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K.-I., Ginsberg, H. N., et al. (2012) · Diabetes · doi:10.2337/db11-1506 · Cited by 292 · cited 1×
“M2-polarized macrophages generated anti-inflammatory cytokines, reducing both obesity-induced inflammation and insulin resistance in fat and liver tissues, thereby promoting the recovery of normal energy homeostasis [59–61].”
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285 · cited 2×
“This has This has led to the development of tirzepatide, a novel dual GIP/GLP1 receptor agonist [94]. led to the development of tirzepatide, a novel dual GIP/GLP1 receptor agonist [94].”
Obesity subtypes, related biomarkers & heterogeneity
Mayoral, L. P.-C., Andrade, G. M., Mayoral, E. P.-C., Huerta, T. H., Canseco, S. P., Rodal Canales, F. J., Cabrera-Fuentes, H. A., Cruz, M. M., Pérez Santiago, A. D., Alpuche, J. J., et al. (2020) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1768_17 · Cited by 277 · cited 1×
“Overweight and obesity are serious medical conditions and a leading preventable cause of death worldwide, with rates increasing in both adults and children [65].”
Epicardial Fat: Definition, Measurements and Systematic Review of Main Outcomes
Bertaso, A. G., Bertol, D., Duncan, B. B., & Foppa, M. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20130138 · Cited by 268 · cited 1×
“It shares many pathophysiological properties with other visceral fat depots, including local inflammation [35].”
Kario, K., Okada, K., Kato, M., Nishizawa, M., Yoshida, T., Asano, T., Uchiyama, K., Niijima, Y., Katsuya, T., Urata, H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037076 · Cited by 251
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 240 · cited 1×
“On the other hand, targeted trials have reported that GLP1-RA are also effective at reducing body weight and are being further investigated for their mechanism of action [66].”
SGLT2i: beyond the glucose-lowering effect
Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01071-y · Cited by 230 · cited 1×
“Firstly, SGLT2i increase diuresis, glucose, and sodium excretion, resulting in a reduction of plasma volume, atrial blood pressure, and atrial dilation effects [45].”
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223 · cited 3×
“Numerous studies have demonstrated significant anti-inflammatory and anti-fibrotic effects of both classes of drugs, both in vitro and in vivo [24,25].”
Tian, J., Zhang, M., Suo, M., Liu, D., Wang, X., Liu, M., Pan, J., Jin, T., & An, F. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16601 · Cited by 212
(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000178 · Cited by 211
Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage
Liu, Q., Wang, S., & Cai, L. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12250 · Cited by 206 · cited 2×
“…[6]. production can deteriorate the formation of advanced glycation end products (AGEs), activate receptors for AGEs (RAGE) and protein kinase C (PKC) isoforms, increase the flux of the hexosamine pathway, and activate the NF-κ B pathway [5], indirectly leading to diabetic cardiomyopathy [6].”
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202 · cited 3×
“Early studies have already assessed the safety, pharmacokinetics, and pharmacodynamics of retatrutide [102].”
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Ghanim, H., Abuaysheh, S., Hejna, J., Green, K., Batra, M., Makdissi, A., Chaudhuri, A., & Dandona, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa057 · Cited by 197 · cited 1×
“In addition, there is evidence to suggest a direct effect of SGLT2i on hematocrit levels [52,53].”
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Packer, M. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00824-4 · Cited by 185 · cited 6×
“Autophagy is a cellular process that clears cells from dysfunctional organelles as well as toxic glucose and lipid by-products [56].”
InfluentialAdingupu, D. D., Göpel, S. O., Grönros, J., Behrendt, M., Sotak, M., Miliotis, T., Dahlqvist, U., Gan, L.-M., & Jönsson-Rylander, A.-C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0820-6 · Cited by 172
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 171
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.033 · Cited by 166 · cited 1×
“In vitro studies on human fibroblasts have shown that the SGLT2i induce a quiescent-like phenotype, reduce the extracellular matrix remodeling response, and decrease the expression of profibrotic markers [26].”
Nasiri-Ansari, Ν., Dimitriadis, G. K., Agrogiannis, G., Perrea, D., Kostakis, I. D., Kaltsas, G., Papavassiliou, A. G., Randeva, H. S., & Kassi, E. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0749-1 · Cited by 159
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155 · cited 2×
“Treatment with SGLT2i not only attenuates inflammation but also reduces indicators of oxidative stress in both the cardiomyocyte and vascular environment, leading to a restoration of nitric oxide (NO) bioavailability and providing vascular protective effects [69,76].”
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144 · cited 2×
“95].”
Xu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134 · cited 4×
“Numerous in vivo studies have confirmed the metabolic changes induced by SGLT2i and revealed several side benefits [59].”
InfluentialEpicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation
Conte, M., Petraglia, L., Cabaro, S., Valerio, V., Poggio, P., Pilato, E., Attena, E., Russo, V., Ferro, A., Formisano, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932262 · Cited by 132 · cited 1×
“Another proposed effect of SGLT2i is related to the increased volume of EAT in patients with T2DM, which leads to localized inflammation via adipokines and possibly increases the incidence of AF [47].”
Self-citationCappetta, D., De Angelis, A., Ciuffreda, L. P., Coppini, R., Cozzolino, A., Miccichè, A., Dell'Aversana, C., D’Amario, D., Cianflone, E., Scavone, C., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104781 · Cited by 128 · cited 1×
“Treatment with SGLT2i not only attenuates inflammation but also reduces indicators of oxidative stress in both the cardiomyocyte and vascular environment, leading to a restoration of nitric oxide (NO) bioavailability and providing vascular protective effects [69,76].”
Li, X., Lü, Q., Qiu, Y., do Carmo, J. M., Wang, Z., da Silva, A. A., Mouton, A. J., Omoto, A. C. M., Hall, M. E., Li, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018298 · Cited by 127 · cited 1×
“Recent studies have suggested a potential interaction between SGLT2i and glucose transporter 1 (GLUT1) [63], which normally facilitates the transport of glucose across plasma membranes in almost all tissues.”
Liu, Q., Anderson, C., Broyde, A., Polizzi, C., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 124 · cited 1×
“In addition, in rats with MI-induced chronic heart failure, GLP1 treatment showed the capability to arrest adverse cardiac remodeling [31].”
Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J.-F., Thai, K., & Gilbert, R. E. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 120
Zhou, Z., Jardine, M. J., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031623 · Cited by 117 · cited 2×
“The results consistently indicated that SGLT2i could prevent both AF and AFL without significantly affecting the overall stroke risk [43].”
Lambert, R., Srodulski, S., Peng, X., Margulies, K. B., Despa, F., & Despa, S. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002183 · Cited by 114
Uthman, L., Li, X., Baartscheer, A., Schumacher, C. A., Baumgart, P., Hermanides, J., Preckel, B., Hollmann, M. W., Coronel, R., Zuurbier, C. J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112515 · Cited by 111
Byrne, N. J., Soni, S., Takahara, S., Ferdaoussi, M., Batran, R. A., Darwesh, A. M., Levasseur, J. L., Beker, D. L., Vos, D. Y., Schmidt, M. A., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006573 · Cited by 110 · cited 1×
“Numerous studies have demonstrated significant anti-inflammatory and anti-fibrotic effects of both classes of drugs, both in vitro and in vivo [24,25].”
Terasaki, M., Hiromura, M., Mori, Y., Kohashi, K., Nagashima, M., Kushima, H., Watanabe, T., & Hirano, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143396 · Cited by 107 · cited 1×
“In addition, it has been demonstrated that the SGLT2i not only attenuate macrophage recruitment and infiltration but also favor M1 to M2 phenotype macrophage polarization, thereby reducing the inflammatory and oxidative environment and preventing foam cell formation [75].”
Packer, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad235 · Cited by 107 · cited 1×
“Although it is assumed that the increased EPO production is related to the improved renal function resulting from this drug class, there may be a more direct mechanism that has yet to be identified [1,54,55].”
Monji, A., Mitsui, T., Bando, Y. K., Aoyama, M., Shigeta, T., & Murohara, T. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00990.2012 · Cited by 104 · cited 1×
“In animal models, GLP1-RA can improve myocardial oxidative stress through suppression of NOX-4, with a concomitant increase in superoxide dismutase 1 (SOD-1) and glutathione peroxidase [20].”
Epicardial fat: a new cardiovascular therapeutic target
Iacobellis, G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.004 · Cited by 104 · cited 3×
“These findings are particularly interesting since the GLP1 receptor is overexpressed in the visceral adipose depots of obese patients [40].”
InfluentialInoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., & Takayanagi, R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.026 · Cited by 103 · cited 1×
“Additionally, GLP1-RA can reduce myocardial triglyceride and diacylglycerol levels, NOX activity, and oxidative stress through activation of the AMPK-Sirt1 pathway [21].”
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93
Self-citationWu, L., Wang, K., Wang, W., Wen, Z., Wang, P., Liu, L., & Wang, D. W. (2018) · Aging Cell · doi:10.1111/acel.12763 · Cited by 92
Nakatsu, Y., Kokubo, H., Bumdelger, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M.-K., Fujishiro, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081704 · Cited by 89 · cited 1×
“Specifically, they inhibit pro-inflammatory cytokines, such as IL-1 β , IL-6, and TNF-α , as well as attenuate NLRP3 inflammasome activation [70,71].”
Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83 · cited 2×
“They improve lipid parameters by lowering total cholesterol, LDL cholesterol, and triglyceride concentrations and increasing HDL cholesterol levels [78].”
Nuamnaichati, N., Mangmool, S., Chattipakorn, N., & Parichatikanond, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00805 · Cited by 81
Zheng, R.-J., Wang, Y., Tang, J.-N., Duan, J.-Y., Yuan, M.-Y., & Zhang, J.-Y. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001183 · Cited by 80 · cited 5×
“This correlates with a reduction in myocardial hypertrophy, fibrosis, and adverse remodeling, thereby reducing the risk of arrhythmia [42].”
InfluentialWallenius, K., Kroon, T., Hagstedt, T., Löfgren, L., Sörhede‐Winzell, M., Boucher, J., Lindén, D., & Oakes, N. D. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100176 · Cited by 80 · cited 4×
“As anticipated, SGLT2i induce a recovery shift of metabolism from glucose to FFA, enhancing their transport and β -oxidation in the heart [57].”
InfluentialMartins, F. L., Bailey, M. A., & Girardi, A. C. C. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14868 · Cited by 74 · cited 1×
“Other factors that may contribute to blood pressure reduction are the anti-inflammatory effect and the role of Na + /H + exchange on the proximal tubule [88].”
Spigoni, V., Fantuzzi, F., Carubbi, C., Pozzi, G., Masselli, E., Gobbi, G., Solini, A., Bonadonna, R. C., & Dei, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01016-5 · Cited by 73 · cited 1×
“Furthermore, SGLT2i promote plaque stabilization by reducing the activity of metalloproteinase-2 (MMP-2) and overall improving vascular fitness [73].”
Zhang, L., Tian, J., Diao, S., Zhang, G., Xiao, M., & Chang, D. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109252 · Cited by 73
Croteau, D., Luptak, I., Chambers, J. M., Hobai, I., Panagia, M., Pimentel, D. R., Siwik, D. A., Qin, F., & Colucci, W. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019995 · Cited by 73
Rizvi, A. A., & Rizzo, M. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s351982 · Cited by 65 · cited 2×
“These agents have the ability to activate both the GLP1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, leading to enhanced glucose control, weight loss, and improvements in cardiovascular risk factors such as blood pressure and lipid profiles [90].”
Wang, J., Huang, X., Liu, H., Chen, Y., Li, P., Liu, L., Li, J., Ren, Y., Huang, J., Xiong, E., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1122494 · Cited by 65 · cited 2×
“…ATP production [12]. addition, SGLT2i can prevent cardiac dysfunction by improving oxidative stress and mitochondrial dysfunction in animal models [10] via the stimulation of Nrf2/ARE signaling and suppression of the TGF-β /Smad pathway [11], preventing hydrogen peroxide release and preserving…”
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Rahadian, A., Fukuda, D., Salim, H. M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.52100 · Cited by 63
Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63 · cited 2×
“Several dual-receptor agonists are currently in development, and early clinical studies have shown promising results [91] (Figure 2).”
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., & von Lewinski, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031678 · Cited by 60 · cited 4×
“The role of SGLT2i in reducing EAT, as discussed previously, may contribute to their anti-arrhythmic action [42,44].”
InfluentialIacobellis, G., & Baroni, M. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 56 · cited 1×
“Increasing evidence suggests that EAT plays an important role in cardiometabolic risk and is involved in the progression of coronary artery disease (CAD), heart failure, and atrial fibrillation (AF) [36,37].”
van Ruiten, C. C., Smits, M. M., Kok, M. D., Serné, E. H., van Raalte, D. H., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01492-x · Cited by 55 · cited 2×
“Differently, GLP-1RA show a lack of diastolic blood pressure-lowering effects and a slight increase in heart rate in the early stages of administration [50,85].”
McCormick, L. M., Hoole, S. P., White, P. A., Read, P. A., Axell, R. G., Clarke, S. J., O’Sullivan, M., West, N. E. J., & Dutka, D. P. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.09.014 · Cited by 54 · cited 1×
“Indeed, the pre-treatment with GLP1 (7–36) amide can protect the heart against ischemic left ventricular dysfunction and improve its recovery during reperfusion [32].”
Aberle, J., Menzen, M., Schmid, S. M., Terkamp, C., Jaeckel, E., Rohwedder, K., Scheerer, M. F., Xu, J. L., Tang, W., & Birkenfeld, A. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-78734-z · Cited by 53
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43 · cited 2×
“Indeed, the combination of antihypertensive drugs and SGLT2i in patients with diabetes improved blood pressure control more than the combination with GLP1RA [82,83].”
Sakurai, S., Jojima, T., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107703 · Cited by 40
Li, F.-F., Gao, G., Li, Q., Zhu, H., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5347262 · Cited by 39
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes
Zhao, N., Wang, X., Wang, Y., Yao, J., Shi, C., Du, J., & Bai, R. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5578216 · Cited by 37 · cited 1×
“In diabetes, EAT is significantly thicker compared to controls and has a greater degree of inflammation, which is associated with systolic-diastolic dysfunction, CAD, worse cardiopulmonary fitness, and higher mortality [38].”
Qian, P., Tian, H., Wang, Y., Lu, W., Li, Y., Ma, T., Gao, X., & Yao, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114209 · Cited by 36 · cited 1×
“Regarding the effect of GLP1-RA on oxidative stress, it is known that a novel oral GLP-1RA hypoglycemic peptide 2 (OHP2) and exendin-4 inhibited neutral lipid accumulation as well as intracellular and mitochondrial ROS generation in palmitate-or methylglyoxal-induced rat cardiomyocytes [16–18].”
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101390 · Cited by 36 · cited 2×
“Recent studies have evaluated the correlation between glucose-lowering agents and the risk of AF/AFL, comparing SGLT2i and GLP1-RA [48].”
Pignatelli, P., Baratta, F., Buzzetti, R., D’Amico, A., Castellani, V., Bartimoccia, S., Siena, A., D’Onofrio, L., Maddaloni, E., Pingitore, A., et al. (2022) · Antioxidants · doi:10.3390/antiox11101878 · Cited by 33 · cited 1×
“Meanwhile, a pilot study measuring the blood levels of soluble NADPH oxidase 2 (NOX2)-derived peptide, which is a marker of NOX2 activation and hydrogen peroxide production in patients with T2DM, showed that SGLT2i significantly reduced the level of both markers [15].”
Wang, D., Jiang, L., Feng, B., He, N., Zhang, Y., & Ye, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13098 · Cited by 32 · cited 3×
“In this context, increased fibrosis occurs in association with myocyte loss, further exacerbating myocardial stiffness and eventually leading to cardiac diastolic and systolic dysfunction [30].”
InfluentialKing, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30 · cited 1×
“Furthermore, emerging evidence suggests that SGLT2i and GLP1-RA provide signifi-cant therapeutic benefits in patients with pulmonary hypertension by favoring recovered hemodynamics in the right ventricle and pulmonary vascular remodeling [89].”
Trombara, F., Cosentino, N., Bonomi, A., Ludergnani, M., Poggio, P., Gionti, L., Baviera, M., Colacioppo, P., Roncaglioni, M. C., Leoni, O., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01758-y · Cited by 25 · cited 1×
“Moreover, chronic therapy with GLP-1 RA and/or SGLT-2i has a positive effect on the clinical out-Antioxidants comes of patients with diabetes mellitus who are hospitalized due to acute myocardial infarction [33].”
Self-citationBami, K., Gandhi, S., Leong-Poi, H. M., Yan, A. T.-K., Ho, E. C., Zahrani, M., Garg, V., Zuo, F., Teoh, H., Quan, A., et al. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.02.005 · Cited by 22
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 22 · cited 1×
“There is a growing body of evidence that suggests cardiometabolic drugs have benefi-cial effects not only on the heart but also on the vascular system, particularly in the context of peripheral artery disease [68].”
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22 · cited 2×
“…drug demonstrated a significant reduction in the number of subjects affected by metabolic syndrome, which encompasses a combination of high-weight-associated cardiovascular risk factors such as obesity, hypertension, high triglyceride levels, low HDL cholesterol, and impaired glucose tolerance [98].”
Li, H., Xu, X., Wang, J., Kong, X., Chen, M., Jing, T., Zhang, Z., Yin, G., Liu, X., Hu, Y., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/6423987 · Cited by 21 · cited 1×
“…report also indicates that plasma levels of 8-iso-PGF2 α are reduced after 26 weeks of GLP1-RA administration in patients with T2DM, suggesting a reduction in oxidative stress through reduced ROS production and increased antioxidant capacity, partly independent of the glucose-lowering effect [22].”
Sawami, K., Tanaka, A., & Node, K. (2023) · Hypertension Research · doi:10.1038/s41440-023-01324-9 · Cited by 20 · cited 1×
“Another interesting effect of SGLT2i and GLP1-RA, contributing to cardioprotection, is related to the reduction of blood pressure [79].”
Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
Al‐Thani, N. A., Hasan, M. H., & Yalcin, H. C. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10379-5 · Cited by 18 · cited 1×
“Specifically, a lower cardiac and peripheral activation of NLRP3 inflammasome and ROS production was observed [27].”
Sawami, K., Tanaka, A., & Node, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01611-8 · Cited by 15 · cited 1×
“Instead, it has been demonstrated that GLP-1RA intake acts on weight loss through appetite suppression [86] and antiproliferative actions in vascular smooth muscle cells [87], which in turn could contribute to blood pressure reduction.”
Vrachatis, D. A., Papathanasiou, K. A., Iliodromitis, K. E., Giotaki, S. G., Kossyvakis, C., Raisakis, K., Kaoukis, A., Lambadiari, V., Avramides, D., Reimers, B., et al. (2021) · Drugs · doi:10.1007/s40265-021-01565-3 · Cited by 14 · cited 1×
“On the other hand, GLP1-RA have demonstrated a reduction in stroke but does not significantly prevent the onset of AF/AFL [49].”
Cessario, J., Pierre-Louis, V., Wahl, J., & Li, Z. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00224-4 · Cited by 13
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Sato, K., Terauchi, Y., Tamura, K., & Kanamori, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20313-5 · Cited by 12 · cited 2×
“Indeed, the combination of antihypertensive drugs and SGLT2i in patients with diabetes improved blood pressure control more than the combination with GLP1RA [82,83].”
Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy
Iacobellis, G., Basilico, S., & Malavazos, A. E. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_577 · Cited by 8 · cited 1×
“Increasing evidence suggests that EAT plays an important role in cardiometabolic risk and is involved in the progression of coronary artery disease (CAD), heart failure, and atrial fibrillation (AF) [36,37].”
Cited by
Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 72
“GLP1RAs can inhibit neutral lipid accumulation, ROS generation, and (NADPH oxidase 4) NOX-4 expression in rat cardiomyocytes, thereby migrating interleukin-1 β (IL-1 β) induced ROS production [57].”
BackgroundMericskay, M., Zuurbier, C. J., Heather, L. C., Karlstaedt, A., Inserte, J., Bertrand, L., Kararigas, G., Ruiz‐Meana, M., Maack, C., & Schiattarella, G. G. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01166-7 · Cited by 80
Mitochondrial Dysfunction in Atrial Fibrillation: The Need for a Strong Pharmacological Approach
Mauriello, A., Correra, A., Molinari, R., Vecchio, G. E. D., Tessitore, V., D’Andrea, A., & Russo, V. (2024) · Biomedicines · doi:10.3390/biomedicines12122720 · Cited by 27
“Fibrates, acting as PPAR-alfa agonists, are commonly utilized to address hypertriglyceridemia, decrease hepatic apolipoprotein C-III (apoC-III) levels, and enhance lipoprotein lipase-mediated lipolysis.”
Little, P. J., Offermanns, S., Cho, H., Liu, Z., Yang, P., Su, Q., Wade, H., Yang, W., Kamato, D., Cohen, N. D., et al. (2026) · iNew Medicine · doi:10.1002/inm3.70028 · Cited by 27
Yang, Y., Liu, W., Zhang, Z., zhang, Y., Wang, X., Wang, J., Cai, H., Liu, Y., Meng, R., Fu, Y., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103414 · Cited by 19
Metadata
- Authors
- Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., Genovese, S., & Poggio, P.
- Affiliations
- Centro Cardiologico Monzino (IT)
- Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
- University of Salerno (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Poggio, Paolo
- ORCID
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2023-12-20
- Volume
- 13
- Issue
- 1
- Pages
- 16
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC10812629
- OpenAlex
- W4389991782
- Cited by
- 35
- References
- 107
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 10
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (PNRR-MAD-2022-12376009, FPF-14)
- Italian Ministry of Health (Ricerca Corrente to Centro Cardiologico Monzino IRCCS) (PNRR-MAD-2022-12376009, FPF-14)
- Fondazone Gigi & Pupa Ferrari ONLUS (PNRR-MAD-2022-12376009, FPF-14)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular disease, anti-inflammatory activity, antioxidant activity, cardioprotection, glucose-lowering therapy, cardiac physiology, myocardial metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.